Ignite Creation Date:
2025-12-24 @ 10:34 PM
Ignite Modification Date:
2025-12-29 @ 6:31 PM
Study NCT ID:
NCT06047535
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-21
First Post:
2023-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
Sponsor:
SciClone Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-06-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-08-15
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-12
First Submit QC Date:
None
Study First Post Date:
2023-09-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-18
Last Update Post Date:
2023-09-21
Last Update Post Date Type:
ACTUAL